Orphazyme-founder on IPO: Now we can take the company all the way

According to co-founder and CEO in Orphazyme, Anders Hinsby, an IPO gives the Danish biotech company a chance to take its products through the last development phase towards a drug approval.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

2017 var et rekordår for kapitalrejsninger i Skandinavien

Skandinaviske life science-selskaber rejste ligeså mange penge i 2017 som i de tre foregående år tilsammen, viser en ny rapport fra svenske Industrifonden. Sverige førte ikke overraskende an, men der var også fremgang at spore i Danmark og Norge.

Related articles